DNTH
HealthcareDianthus Therapeutics, Inc. · Biotechnology · $4B
What is Dianthus Therapeutics, Inc.?
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for people living with severe autoimmune and inflammatory diseases. Based in New York City, the company is advancing its lead candidate through early-stage clinical trials.
Dianthus Therapeutics designs and develops novel monoclonal antibodies targeting the complement and FcRn pathways, which are implicated in debilitating autoimmune conditions. Its lead program, DNTH103, is currently in Phase 1 clinical trials across several rare neuromuscular diseases — including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. As a clinical-stage company, Dianthus does not yet generate product revenue and relies on capital markets to fund its research and development activities.
Dianthus Therapeutics was incorporated in 2018 and is headquartered in New York City, New York.
- DNTH103 monoclonal antibody — lead clinical-stage asset
- Complement pathway targeting for autoimmune disease
- Focus on rare neuromuscular and inflammatory conditions
- Novel antibody engineering platform
Is DNTH a Good Stock to Buy?
UQS Score rates DNTH as Poor overall, reflecting the early-stage nature and inherent uncertainties of clinical-stage biotech investing.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet and near-term financial exposure are managed more carefully than many peers at this stage of development. This is not uncommon for well-capitalized clinical-stage biotechs that have raised sufficient runway.
Quality, Moat, and Growth all register as Weak, which is expected for a pre-revenue company with a single clinical asset. Valuation is rated Elevated, meaning the current market price may already reflect optimistic assumptions about trial outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DNTH pay dividends?
No — Dianthus Therapeutics, Inc. does not currently pay a dividend.
Dianthus Therapeutics does not pay a dividend. As a clinical-stage biotechnology company with no product revenue, all available capital is directed toward advancing DNTH103 through clinical trials and funding ongoing research operations. Income-focused investors should be aware that a dividend is unlikely until the company reaches commercial-stage profitability.
When does DNTH report earnings?
Dianthus Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or earnings metrics. Investors typically monitor pipeline milestones and cash position updates rather than top-line growth.
For the most recent quarter's results and clinical updates, visit Dianthus Therapeutics' investor relations page directly.
DNTH Price History
-54.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Dianthus Therapeutics, Inc.?
Based on Dianthus Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DNTH Long-term Outlook
The fundamental outlook for DNTH is shaped heavily by binary clinical trial risk. With Growth and Quality both rated Weak, the near-term trajectory depends almost entirely on Phase 1 data readouts for DNTH103 rather than organic business expansion. The Elevated Valuation rating suggests the market has priced in some degree of clinical success, which raises the stakes if trial results disappoint. The relatively Good Risk rating provides some reassurance around financial stability in the near term.
Growth drivers
- Positive Phase 1 clinical data for DNTH103 across target indications
- Expanding pipeline or partnership opportunities in rare autoimmune diseases
- Growing unmet medical need in neuromuscular disease treatment
Key risks
- Clinical trial failure or safety signals for DNTH103
- Elevated valuation leaving limited margin of safety if milestones slip
- Ongoing cash burn with no product revenue to offset operating costs
DNTH vs Peers
Dianthus Therapeutics operates in a competitive rare-disease and autoimmune biotech landscape alongside companies at varying stages of development.
Telix focuses on radiopharmaceuticals for oncology and urology, representing a distinct therapeutic modality compared to Dianthus's antibody-based autoimmune approach.
Liquidia is developing inhaled therapies for pulmonary arterial hypertension, targeting a different disease area but competing for similar rare-disease investor attention.
Edgewise targets cardiac and skeletal muscle diseases with small-molecule therapies, sharing the rare neuromuscular disease space with Dianthus but using a different drug modality.
Frequently Asked Questions
What does Dianthus Therapeutics do?
Dianthus Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead asset, DNTH103, is currently in Phase 1 clinical trials targeting rare neuromuscular conditions including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Does DNTH pay dividends?
No, Dianthus Therapeutics does not pay a dividend. The company is pre-revenue and reinvests all available capital into clinical development. A dividend is not expected until the company reaches commercial-stage operations, which remains several years away at minimum.
When does DNTH report earnings?
Dianthus Therapeutics reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, reports focus on cash position and trial progress rather than traditional earnings. Check the company's investor relations page for the most current schedule.
Is DNTH a good stock to buy?
UQS Score rates DNTH as Poor overall. The rating reflects weak Quality, Moat, and Growth scores typical of early-stage clinical biotechs, alongside an Elevated Valuation. The Risk pillar is the relative strength. Whether it suits your portfolio depends on your risk tolerance and investment horizon — view the full breakdown on UQS Pro.
Is DNTH overvalued?
UQS Score's Valuation pillar for DNTH is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about clinical trial success. For a pre-revenue company, valuation is inherently speculative and tied to pipeline outcomes rather than current financial performance.
How does DNTH compare to its competitors?
Dianthus competes in the rare-disease biotech space alongside companies like Edgewise Therapeutics, Liquidia Corporation, and Telix Pharmaceuticals. Each pursues different therapeutic modalities and disease areas. DNTH's differentiation lies in its complement-pathway antibody approach to neuromuscular autoimmune diseases. See the UQS comparison table for a side-by-side quality score view.
What is DNTH's market cap bracket?
Dianthus Therapeutics is classified as a mid-cap company. This places it in a range that attracts both institutional and retail investor interest, though clinical-stage mid-caps carry substantially higher risk than established mid-cap businesses with proven revenue streams.
Who founded Dianthus Therapeutics?
Dianthus Therapeutics was incorporated in 2018. Founding and leadership details are publicly available through the company's official filings and investor relations materials, which provide the most accurate and up-to-date information on its executive history.
Is DNTH a long-term quality investment?
As a long-term quality indicator, UQS Score rates DNTH as Poor — driven by Weak scores across Quality, Moat, and Growth pillars. Long-term quality typically requires durable competitive advantages and consistent financial performance, neither of which a pre-revenue clinical-stage company can yet demonstrate. Clinical success could change this profile materially.
What is the main competitive advantage of Dianthus Therapeutics?
Dianthus's potential advantage lies in its proprietary monoclonal antibody engineering targeting the complement pathway — a mechanism implicated in several underserved autoimmune diseases. However, with a Weak Moat rating from UQS Score, this advantage is not yet considered durable, as the asset remains in early-stage clinical development.
What sector does DNTH belong to?
Dianthus Therapeutics belongs to the Healthcare sector, specifically within clinical-stage biotechnology. This sub-segment is characterized by high risk, binary clinical outcomes, and long development timelines — factors that heavily influence how UQS Score evaluates companies like DNTH across its five pillars.
Is DNTH a growth stock or value stock?
Based on UQS pillar labels, DNTH does not fit neatly into either category. Its Growth pillar is rated Weak — reflecting the absence of revenue — while its Valuation pillar is Elevated, ruling out a traditional value characterization. It is best described as a speculative clinical-stage biotech rather than a conventional growth or value play.
Unlock Full DNTH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS Score and all five pillar scores
- ✓Access detailed financial metrics and trend data
- ✓Compare DNTH against sector peers side by side
- ✓See Risk pillar breakdown and cash runway indicators
- ✓Get the complete analyst-style quality assessment
- ✓Track score changes as new data becomes available
Pro Analysis
DNTH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 10.7 | 0.0 | 14.0 | 0.5 | 47.1 | 0.0 | -0.5 |
| May 10, 2026 | 11.2 | 0.0 | 14.0 | 3.0 | 47.1 | 0.0 | +0.6 |
| May 9, 2026 | 10.6 | 0.0 | 14.0 | 0.0 | 47.1 | 0.0 | -0.9 |
| May 7, 2026 | 11.5 | 0.0 | 14.0 | 4.8 | 47.1 | 0.0 | -3.8 |
| Apr 12, 2026 | 15.3 | 0.0 | 14.0 | 4.8 | 72.6 | 0.0 | +0.7 |
| Apr 2, 2026 | 14.6 | 0.0 | 14.0 | 0.9 | 72.6 | 0.0 | — |
DNTH — Pillar Breakdown
Quality
— 0.0/100 (25%)Dianthus Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 0.5/100 (20%)Dianthus Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)Dianthus Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Dianthus Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Dianthus Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DNTH.
Score Composition
Financial Data
More Stock Analysis
How is the DNTH UQS Score Calculated?
The UQS (Unified Quality Score) for Dianthus Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Dianthus Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Dianthus Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.